India's Brain Cancer Breakthrough? High-Grade Glioma Survival Jumps By Up To 50%

High-grade gliomas are among the most aggressive and difficult-to-treat brain cancers, characterised by rapid growth and poor survival outcomes. These malignant tumours arise from glial cells that support nerve cells in the brain and can cause severe symptoms including headaches, seizures, vision or hearing problems, balance issues, memory loss and speech disorders. In India, central nervous system tumours—including gliomas—affect an estimated 40,000 to 50,000 people annually, with brain tumours accounting for approximately 2% of all cancers diagnosed in the country.However, the survival outcomes for patients with high-grade gliomas are improving in India. Specialists in the Delhi-NCR region report survival gains of up to 50%, with median survival rising

from approximately 9–12 months to 14–18 months. A growing proportion of patients are now surviving two years or more after diagnosis, and a small subset—around 5% in certain high-grade glioma cohorts—are living beyond a decade, according to treating physicians.Experts from leading institutions attribute these improvements to advances across multiple treatment domains. Molecular diagnostics and comprehensive genomic profiling are enabling doctors to tailor therapies to each patient's tumour's genetic profile. Marker analysis for IDH mutations and MGMT status, along with whole genomic sequencing, is increasingly guiding treatment decisions and helping identify patients who may benefit from targeted therapies. Surgical techniques assisted by neuronavigation, precision radiation therapy using multi-leaf collimators, and newer targeted systemic treatments are collectively transforming the glioma treatment landscape.Radiation oncology specialists note that modern equipment allows delivery of tumoricidal doses while better protecting healthy tissue, contributing to longer survival and improved quality of life. Medical oncologists like Dr. Tejinder Kataria, Chairperson, Radiation Oncology, Medanta believes that report improved outcomes are seen when patients are evaluated early and managed through multidisciplinary neuro-oncology teams. Newer targeted therapies and appropriately selected chemotherapies are also extending survival for some patients with recurrent disease. "The overall survival or the median survival was around 9 to 12 months. It has moved to 14 to 18 months. Our survival of our patients with neuronavigation and radiation for grade 3 and grade 4 gliomas is almost 40% in two years.", he said.Clinicians stress, however, that delayed diagnosis continues to limit potential gains. Many patients reach neuro-oncology specialists only after symptoms have significantly progressed. Headaches, visual disturbances or hearing loss—common early warning signs—are often treated for extended periods as stress-related pain, migraine or other common conditions, delaying specialist referral. According to Dr. Shyam Agarwal, Senior Consultant, Medical Oncology, Sir Ganga Ram Hospital, this contributes to delayed diagnosis compared with many Western countries. He also noted that specialists in Delhi-NCR are seeing younger patients presenting with astrocytoma and glioma.Doctors also note gliomas are diagnosed across a broad adult age spectrum, from the third decade through the eighth decade of life. Specialists in Delhi-NCR are observing younger patients presenting with astrocytoma and glioma. Despite progress, gliomas remain among the most challenging cancers to treat.From a global research perspective, experts say glioma treatment is increasingly moving towards precision oncology, where therapeutic decisions are guided by tumour biology and molecular alterations rather than tumour location alone. Dr. R. Ranga Rao, Chairman – Medical Oncology, Paras Health , said, "Brain tumour treatment is no longer limited to surgery and radiation alone. The growing understanding of tumour biology is helping us tailor treatment according to the molecular profile of each patient's disease. Markers such as IDH mutations, MGMT status, and insights gained through comprehensive genomic sequencing are increasingly influencing treatment decisions and helping us identify patients who may benefit from targeted therapies.Industry and clinical leaders point to ongoing experimentation with next-generation immunotherapies and CAR T-cell therapies in gliomas, with some results described as outstanding. Dr. Pranav Sopory, Medical and Patient Affairs Director, Servier India, said, “It's no longer a one-size-fits-all disease. It's largely a precision oncology-driven therapy area. You have to check for mutations such as IDH1 and 2, MGMT and 1P19.Specialists urge strengthening India's clinical trial ecosystem and innovating public insurance schemes such as Ayushman Bharat to enable earlier access to innovative therapies. They recommend formal spaces for multidisciplinary team discussions so Indian patients with these difficult-to-treat cancers can access cutting-edge treatments and achieve the best possible outcomes.Across institutions, clinicians emphasise that while gliomas remain among the most difficult cancers to treat, advances in precision diagnostics, targeted therapies, modern radiation techniques and multidisciplinary care are steadily changing outcomes. They stress that greater awareness of warning signs, earlier referral to specialists and wider access to genomic testing will be critical to ensuring more patients benefit from these advances.